OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Tsao on First-line Treatment Approaches in Clear Cell RCC

May 11th 2023

Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.

Dr Anderson on Novel and Emerging Therapeutics in HR+ Breast Cancer

May 11th 2023

Karen S. Anderson, MD, PhD, discusses novel and emerging therapies, as well as potential future targets, for the treatment of patients with hormone receptor–positive breast cancer.

Dr Das on the Limited Landscape of Second-line Treatment Options in ES-SCLC

May 11th 2023

Devika Das, MD, MSHQS, discusses the activity and tolerability of lurbinectedin and topotecan as second-line regimens in extensive-stage small cell lung cancer.

Dr Paz-Ares on the Challenges of NGS in NSCLC

May 10th 2023

Luis G. Paz-Ares, MD, PhD, discusses the importance of next-generation sequencing and highlights current challenges with NGS for patients with non–small cell lung cancer.

Dr Shore on the Rationale for the EMBARK Trial in Nonmetastatic Prostate Cancer

May 10th 2023

Neal Shore, MD, FACS, discusses the rationale for the phase 3 EMBARK trial investigating enzalutamide plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Dr Mohan on AEs Associated With CAR T-cell Therapy in R/R Myeloma

May 10th 2023

Meera Mohan, MD, MS, FACP, discusses adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr Jain on Baseline Differences Across Different Donor Types in Myelofibrosis

May 10th 2023

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

Dr Desai on Toxicities Associated with T-DXd in HER2+ Breast Cancer

May 10th 2023

Neelam Desai, MD, discusses the toxicity profile of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr Hecht on the Investigation of A2B530 in Germline HLA-A*02 Heterozygous Solid Tumors

May 9th 2023

J. Randolph Hecht, MD, discusses the investigation of A2B530 in germline HLA-A*02 heterozygous solid tumors.

Dr Anderson on the Evolution of ADCs in Metastatic Breast Cancer

May 9th 2023

Karen S. Anderson, MD, PhD, discusses the evolution of antibody-drug conjugates in the treatment of different subgroups of patients with metastatic breast cancer.

Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

May 9th 2023

Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.

Dr Park on Navigating of Later-line Treatment Options in Metastatic Urothelial Carcinoma

May 9th 2023

Chandler Park, MD, MSc, FACP, discusses the navigation and selection of later-line treatments for patients with metastatic urothelial carcinoma.

Dr Galsky on the Need for Novel Drug Classes and Non–Cross-Resistant Options in mRCC

May 8th 2023

Matthew Galsky, MD, explains how the development of novel drug classes and therapeutic combinations could address unmet needs in patients with metastatic renal cell carcinoma.

Dr Marshall on Key Takeaways from the 2023 SOGO Annual Meeting in GI Cancer

May 8th 2023

John L. Marshall, MD, discusses the key takeaways from the 8th Annual School of Gastrointestinal Oncology® and remaining unmet needs for patients with metastatic colorectal cancer.

Dr Habermann on the Evolving Treatment Landscape of Mantle Cell Lymphoma

May 8th 2023

Thomas M. Habermann, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Dr Bal on the Evolution of CAR T-cell Therapy in Multiple Myeloma

May 8th 2023

Susan Bal, MD, discusses the evolution of CAR T-cell therapy in multiple myeloma.

Dr Holowatyj on the Potential Role of Germline Genetic Features in Appendiceal Cancer Susceptibility

May 8th 2023

Andreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.

Dr Malalur on Addressing Unmet Needs in Pancreatic Cancer

May 8th 2023

Pannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.

Dr Murciano-Goroff on the Evaluation of LY3537982 in KRAS G12C–Mutated NSCLC, CRC and Other Solid Tumors

May 5th 2023

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the evaluation of LY3537982 in patients with KRAS G12C–mutated non–small cell lung cancer, colorectal cancer, and other solid tumors.

Dr Bagegni on the Prevalence of ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 5th 2023

Nusayba Bagegni, MD, discusses the prevalence of interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.